3aZEVvoRtp6McXy8TuIlR6lERn067Z

Investor Relations

NYSE: NVRO

Price

42.50 -1.54 ( -3.5% ) 4:02 1/18/19 Pricing delayed 20 minutes

Volume 1,507,414

Recent News

See All
January 7, 2019 Nevro Announces Preliminary Unaudited Fourth Quarter and Full Year 2018 Revenue
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2018. Fourth Quarter 2018 The company announced that preliminary unaudited fourth quarter 2018 worldwide revenue is expected to be in the range of $107.6 to $108.1 million, compared to $98.0 million in the prior year quarter.  Preliminary unaudited U.S. revenue for the fourth quarter of 2018 is expected to be in the range of $91.5 to $91.8 million, compared to $81.1 million in the prior year quarter.  Preliminary unaudited international revenue for the fourth quarter of 2018 is expected to be in the range of $16.1 to $16.3 million, compared to $16.9 million in the prior year quarter. Full Year 2018 Nevro's preliminary unaudited full year 2018 revenue is expected to be in the range of $386.9 to $387.4 million, compared to $326.7 million...
December 20, 2018 Nevro to Present at the 37th Annual J.P. Morgan Healthcare Conference
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the company will be participating in the upcoming 37 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Nevro's management is scheduled to present on Wednesday, January 9, 2019 at 10:30am Pacific Time.  Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company's website at: www.nevro.com. About Nevro Corp. Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The Senza® System and Senza II™ System are the only...
November 5, 2018 Nevro Reports Third Quarter 2018 Financial Results
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three and nine months ended September 30, 2018. Third Quarter Financial Results Revenue for the three months ended September 30, 2018 was $95.6 million versus $82.3 million during the same period of the prior year, representing 16% growth as reported. U.S. revenue for the three months ended September 30, 2018 was $79.6 million, representing 20% growth. International revenue was $16.0 million, representing growth of 4% in constant currency. The increase in revenue was primarily attributable to the continued adoption of the Senza system. Gross profit for the three months ended September 30, 2018 was $67.2 million, representing a 70% gross margin, up from $57.9 million, representing a 70% gross margin, in the same period of the prior year. Operating expenses for the three months ended September 30, 2018...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.